Group 1 - argenex SE (ARGX) is a notable stock in the Medical sector, currently outperforming its peers with a year-to-date return of approximately 54.7% compared to the sector average of 3.1% [4] - The Medical group ranks 4 within the Zacks Sector Rank, which includes 16 different groups [2] - The Zacks Rank system indicates that argenex SE has a Zacks Rank of 2 (Buy), with a significant increase of 478% in the consensus estimate for full-year earnings over the past three months, reflecting improved analyst sentiment [3] Group 2 - argenex SE belongs to the Medical - Biomedical and Genetics industry, which consists of 504 companies and currently ranks 94 in the Zacks Industry Rank, while this industry has seen an average loss of 2.3% this year [5] - Another outperforming stock in the Medical sector is Novartis (NVS), which has a year-to-date return of 9.5% and also holds a Zacks Rank of 2 (Buy) [4][5] - The Large Cap Pharmaceuticals industry, where Novartis is categorized, has 12 stocks and has increased by 12.7% since the beginning of the year, ranking 88 in the Zacks Industry Rank [6]

Company Overview - Argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, which is available in multiple regions including the U.S., Japan, Israel, the EU, the UK, China, and Canada [3] - Argenx is actively evaluating its drug efgartigimod in various serious autoimmune diseases and is advancing several earlier-stage experimental medicines [3] Upcoming Events - Members of the management team will participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 2:30 p.m. ET in Boston, MA [1] - Management will also engage in investor meetings at the Jefferies London Healthcare Conference on November 20 and 21, 2024, in London, UK [2] - A live webcast of the Guggenheim fireside chat will be available on the company's investor website, with a replay accessible for approximately 90 days [2]

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Argenx (NASDAQ: ARGX ) reported strong third quarter results, beating co ...

argenx SE (NASDAQ:ARGX) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Beth DelGiacco – Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren – Chief Executive Officer Karl Gubitz – Chief Financial Officer Karen Massey – Chief Operating Officer Conference Call Participants Derek Archila – Wells Fargo Tazeen Ahmad – Bank of America James Gordon – JPMorgan Allison Bratzel – Piper Sandler Myles Minter – William Blair Alex Thompson – Stifel Danie ...

| --- | --- | --- | --- | --- | --- | --- | |-------------|-------|-------|-------------------------|-----------------------------------------------------|-----------|-------| | | | | | | | | | | | | | | | | | 3 Q 2 0 2 | 4 | | E A R N I N G S C A L L | Reaching Patients Through \| O c t o b e r 3 1 | , 2 0 2 4 | | | | | | | Immunology Innovation | | | | | | | | | | | Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and n ...

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/inv ...

VYVGART and VYVGART Hytrulo Efficacy and Safety - VYVGART demonstrates rapid, deep, and sustained responses in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [4] - More than 50% of gMG patients show substantial and sustained reduction in steroid use after VYVGART initiation [1] - VYVGART Hytrulo shows sustained functional benefit in motor function and muscle strength in CIDP patients, regardless of prior treatment [5] - VYVGART has a consistent and favorable safety profile with over 8,000 patient years of safety data [6] Real-World Data and Clinical Studies - Real-world data show 55% of gMG patients reduced corticosteroid use by ≥5 mg/day one year post VYVGART initiation [5] - 42% of gMG patients achieved steroid doses of ≤5mg/day after one year of VYVGART treatment [5] - Phase 3 studies are ongoing for seronegative and ocular MG populations, showing consistent and clinically meaningful improvements [5] Pipeline Expansion in Neurology - argenx is advancing empasiprubart for multifocal motor neuropathy (MMN) and ARGX-119 for amyotrophic lateral sclerosis (ALS) and congenital myasthenic syndromes (CMS) [9] - Phase 2 ARDA study shows empasiprubart reduces IVIg retreatment risk by 91% and improves grip strength in MMN patients [10] - A Phase 3 study of empasiprubart in MMN is set to start by the end of 2024 [10] Immunology Pipeline Highlights - argenx is evaluating empasiprubart in multiple autoimmune indications, including delayed graft function, dermatomyositis, and CIDP [32] - ARGX-119, a muscle-specific kinase (MuSK) agonist, is being developed for neuromuscular diseases [34] - The company continues to expand its neurology pipeline to deliver transformative outcomes for patients [3] Market and Regulatory Position - VYVGART is the first approved FcRn blocker in the US, EU, China, and Canada for gMG treatment [28] - VYVGART Hytrulo is the first-and-only approved FcRn blocker administered by subcutaneous injection [29] - argenx is committed to improving the lives of patients with severe autoimmune diseases through its immunology pipeline [38]

After grappling with recession fears, the Federal Reserve’s jumbo interest rate cuts helped the broader S&P 500 to defy the odds of a notorious September and notch record highs. The S&P 500 posted its best three-quarters of the 21st century, and if history is any guide, the index is well-poised to continue its winning streak over the next three months. The 30-stock Dow and the tech-laden Nasdaq also closed in the green in the first nine months of 2024. Thus, it’s judicious for astute investors to place thei ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people sufferi ...